281 related articles for article (PubMed ID: 31143523)
1. Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Liu S; Zhang C; Maimela NR; Yang L; Zhang Z; Ping Y; Huang L; Zhang Y
Oncoimmunology; 2019; 8(7):1601478. PubMed ID: 31143523
[TBL] [Abstract][Full Text] [Related]
2. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma.
Zhang C; Zhang Z; Li F; Shen Z; Qiao Y; Li L; Liu S; Song M; Zhao X; Ren F; He Q; Yang B; Fan R; Zhang Y
Oncoimmunology; 2018; 7(11):e1461304. PubMed ID: 30377558
[No Abstract] [Full Text] [Related]
3. Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma.
Yuan Y; Zhao Q; Zhao S; Zhang P; Zhao H; Li Z; Du Y; Tian X; Lu J
Cancer Med; 2019 Jul; 8(8):3811-3821. PubMed ID: 31140757
[TBL] [Abstract][Full Text] [Related]
4. Immune and Clinical Features of
Zhang Q; Zhong H; Fan Y; Liu Q; Song J; Yao S; Cao F
Front Bioeng Biotechnol; 2020; 8():592. PubMed ID: 32695752
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients.
Liu C; Zhang Z; Ping Y; Qin G; Zhang K; Maimela NR; Huang L; Yang S; Zhang Y
Cancer Manag Res; 2020; 12():4399-4410. PubMed ID: 32606935
[TBL] [Abstract][Full Text] [Related]
6. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
[TBL] [Abstract][Full Text] [Related]
7. Large-Scale Analysis Reveals the Specific Clinical and Immune Features of DGCR5 in Glioma.
Wu X; Hou P; Qiu Y; Wang Q; Lu X
Onco Targets Ther; 2020; 13():7531-7543. PubMed ID: 32801772
[TBL] [Abstract][Full Text] [Related]
8. Specific clinical and immune features of CD68 in glioma via 1,024 samples.
Wang L; Zhang C; Zhang Z; Han B; Shen Z; Li L; Liu S; Zhao X; Ye F; Zhang Y
Cancer Manag Res; 2018; 10():6409-6419. PubMed ID: 30568502
[TBL] [Abstract][Full Text] [Related]
9. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.
Wang Z; Zhang C; Liu X; Wang Z; Sun L; Li G; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Oncoimmunology; 2016; 5(11):e1196310. PubMed ID: 27999734
[No Abstract] [Full Text] [Related]
10. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.
Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN
Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967
[No Abstract] [Full Text] [Related]
11. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L
Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110
[TBL] [Abstract][Full Text] [Related]
12. CD44-Mediated Poor Prognosis in Glioma Is Associated With M2-Polarization of Tumor-Associated Macrophages and Immunosuppression.
Xiao Y; Yang K; Wang Z; Zhao M; Deng Y; Ji W; Zou Y; Qian C; Liu Y; Xiao H; Liu H
Front Surg; 2021; 8():775194. PubMed ID: 35187044
[TBL] [Abstract][Full Text] [Related]
13. Uridine phosphorylase 1 is a novel immune-related target and predicts worse survival in brain glioma.
Wang J; Xu S; Lv W; Shi F; Mei S; Shan A; Xu J; Yang Y
Cancer Med; 2020 Aug; 9(16):5940-5947. PubMed ID: 32583596
[TBL] [Abstract][Full Text] [Related]
14. Stanniocalcin 1 is a prognostic biomarker in glioma.
Luo W; Chen D; Wang H; Hu J
Oncol Lett; 2020 Sep; 20(3):2248-2256. PubMed ID: 32782542
[TBL] [Abstract][Full Text] [Related]
15. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma.
Tan YQ; Li YT; Yan TF; Xu Y; Liu BH; Yang JA; Yang X; Chen QX; Zhang HB
Front Immunol; 2020; 11():606164. PubMed ID: 33408717
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Activation of lncRNA MIR155HG Mediated by Promoter Hypomethylation and SP1 is Correlated with Immune Infiltration in Glioma.
Wu X; Wan Q; Wang J; Hou P; Zhang Q; Wang Q; Lu X
Onco Targets Ther; 2022; 15():219-235. PubMed ID: 35299997
[TBL] [Abstract][Full Text] [Related]
17. Long Non-coding RNA Expression Profiling Identifies a Four-Long Non-coding RNA Prognostic Signature for Isocitrate Dehydrogenase Mutant Glioma.
Chen Y; Guo Y; Chen H; Ma F
Front Neurol; 2020; 11():573264. PubMed ID: 33329315
[No Abstract] [Full Text] [Related]
18. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
Front Oncol; 2021; 11():611038. PubMed ID: 33937022
[TBL] [Abstract][Full Text] [Related]
19. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples.
Di W; Fan W; Wu F; Shi Z; Wang Z; Yu M; Zhai Y; Chang Y; Pan C; Li G; Kahlert UD; Zhang W
Cancer Sci; 2022 Feb; 113(2):756-769. PubMed ID: 34881489
[TBL] [Abstract][Full Text] [Related]
20. Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker FAM111A in Diffuse Lower-Grade Glioma.
Ji X; Ding F; Gao J; Huang X; Liu W; Wang Y; Liu Q; Xin T
Front Oncol; 2020; 10():573800. PubMed ID: 33194678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]